Francesc Bosch

15.7k total citations · 2 hit papers
243 papers, 8.7k citations indexed

About

Francesc Bosch is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Francesc Bosch has authored 243 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Genetics, 140 papers in Pathology and Forensic Medicine and 78 papers in Immunology. Recurrent topics in Francesc Bosch's work include Lymphoma Diagnosis and Treatment (137 papers), Chronic Lymphocytic Leukemia Research (130 papers) and Immunodeficiency and Autoimmune Disorders (50 papers). Francesc Bosch is often cited by papers focused on Lymphoma Diagnosis and Treatment (137 papers), Chronic Lymphocytic Leukemia Research (130 papers) and Immunodeficiency and Autoimmune Disorders (50 papers). Francesc Bosch collaborates with scholars based in Spain, United States and Italy. Francesc Bosch's co-authors include Elı́as Campo, Emili Montserrat, Armando López‐Guillermo, Neus Villamor, Dolors Colomer, C Rozmán, Marta Crespo, Beatríz Bellosillo, Marı́a Rozman and Sílvia Marcé and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Francesc Bosch

234 papers receiving 8.6k citations

Hit Papers

ZAP-70 Expression as a Su... 2003 2026 2010 2018 2003 2012 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia
    2003 970 citations Marta Crespo, Francesc Bosch et al. profile →
  2. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
    2012 367 citations Marta Crespo, Francesc Bosch et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Francesc Bosch 5.6k 4.3k 3.4k 2.1k 2.0k 243 8.7k
Sven de Vos 3.9k 0.7× 2.6k 0.6× 3.6k 1.0× 1.3k 0.6× 2.1k 1.1× 192 7.6k
Eric D. Hsi 6.0k 1.1× 3.5k 0.8× 4.7k 1.4× 2.6k 1.3× 3.2k 1.6× 405 12.2k
Brad S. Kahl 7.8k 1.4× 5.1k 1.2× 5.6k 1.6× 1.8k 0.9× 2.4k 1.2× 385 11.3k
Kristie A. Blum 4.4k 0.8× 3.9k 0.9× 2.6k 0.7× 1.4k 0.7× 1.4k 0.7× 207 6.7k
Luca Baldini 3.7k 0.7× 2.8k 0.6× 2.5k 0.7× 1.6k 0.8× 2.3k 1.2× 261 7.8k
Armando López‐Guillermo 8.4k 1.5× 4.4k 1.0× 5.2k 1.5× 2.4k 1.2× 1.8k 0.9× 244 11.5k
Luis Fayad 6.3k 1.1× 2.7k 0.6× 5.5k 1.6× 1.7k 0.8× 1.3k 0.7× 334 9.7k
Iwona Włodarska 4.3k 0.8× 2.4k 0.6× 3.2k 0.9× 1.7k 0.8× 2.2k 1.1× 193 8.6k
Vincent Ribrag 3.6k 0.6× 1.7k 0.4× 4.6k 1.3× 1.5k 0.7× 2.0k 1.0× 309 7.9k
Sonali M. Smith 4.2k 0.7× 2.3k 0.5× 3.3k 1.0× 1.3k 0.6× 1.3k 0.7× 263 6.8k

Countries citing papers authored by Francesc Bosch

Since Specialization
Citations

This map shows the geographic impact of Francesc Bosch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesc Bosch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesc Bosch more than expected).

Fields of papers citing papers by Francesc Bosch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesc Bosch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesc Bosch. The network helps show where Francesc Bosch may publish in the future.

Co-authorship network of co-authors of Francesc Bosch

This figure shows the co-authorship network connecting the top 25 collaborators of Francesc Bosch. A scholar is included among the top collaborators of Francesc Bosch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesc Bosch. Francesc Bosch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tazón‐Vega, Bárbara, Carlos Palacio, V. Navarro, et al.. (2025). How to combine multiple tools for the genetic diagnosis work-up of pediatric B-cell acute lymphoblastic leukemia . Annals of Hematology. 104(4). 2387–2402. 1 indexed citations
2.
Hutchings, Martin, Anna Sureda, Francesc Bosch, et al.. (2025). Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial. Journal of Clinical Oncology. 43(36). 3788–3798.
3.
Navarro, Vı́ctor, Moraima Jiménez, Marc Bosch, et al.. (2025). Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders. Blood Advances. 9(16). 4180–4189. 1 indexed citations
4.
Villasboas, José C., Stephen D. Smith, Carlos Grande, et al.. (2024). Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY).. Journal of Clinical Oncology. 42(16_suppl). 7058–7058. 1 indexed citations
5.
Budde, Lihua E., Sarit Assouline, Laurie H. Sehn, et al.. (2024). Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of Clinical Oncology. 42(19). 2250–2256. 34 indexed citations
6.
Chong, Elise A., Elicia Penuel, Lihua E. Budde, et al.. (2024). Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Blood Advances. 9(4). 696–703. 5 indexed citations
7.
Jiménez, Moraima, Alba Cabirta, Isabel Ruíz-Camps, et al.. (2023). Impact of COVID‐19 infection on bispecific antibodies treatment in patients diagnosed with B‐cell lymphoproliferative disorders. Hematological Oncology. 41(S2). 607–609. 1 indexed citations
8.
Abrisqueta, Pau, Daniel Medina, Guillermo Villacampa, et al.. (2022). A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression. Blood Advances. 6(21). 5763–5773. 2 indexed citations
9.
Jiménez, Moraima, Sabela Bobillo, Alba Cabirta, et al.. (2020). Real-World Data with the Use of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Blood. 136(Supplement 1). 14–16. 2 indexed citations
10.
Fox, María Laura, Irene García‐Cadenas, Ariadna Pérez, et al.. (2020). Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. Leukemia & lymphoma. 61(8). 1823–1832. 2 indexed citations
11.
Scuoppo, Claudio, Jiguang Wang, Mirjana Persaud, et al.. (2019). Repurposing dasatinib for diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences. 116(34). 16981–16986. 27 indexed citations
12.
Lamanna, Nicole, Árpád Illés, Gabriel Étienne, et al.. (2019). Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial. American Journal of Hematology. 94. 1 indexed citations
13.
Blanco, Gonzalo, Anna Vardi, Anna Puiggros, et al.. (2018). Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL. OncoImmunology. 7(6). e1432328–e1432328. 21 indexed citations
14.
García‐Marco, José A., Julio Delgado, José‐Ángel Hernández‐Rivas, et al.. (2017). Actualización de las guías nacionales de consenso del Grupo Español de Leucemia Linfocítica Crónica para el tratamiento y seguimiento de la leucemia linfocítica crónica. Medicina Clínica. 148(8). 381.e1–381.e9. 2 indexed citations
15.
16.
17.
18.
Baptista, Maria João, Ana Muntañola, Pau Abrisqueta, et al.. (2012). Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status. Clinical Cancer Research. 18(21). 5924–5933. 4 indexed citations
19.
Hartmann, Elena, Verónica Fernández, Vı́ctor Moreno, et al.. (2008). Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue. Journal of Clinical Oncology. 26(30). 4966–4972. 85 indexed citations
20.
Enjuanes, Anna, Yolanda Benavente, Francesc Bosch, et al.. (2008). Genetic Variants in Apoptosis and Immunoregulation-Related Genes Are Associated with Risk of Chronic Lymphocytic Leukemia. Cancer Research. 68(24). 10178–10186. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sven de Vos Breakdown of academic impact, for papers by Eric D. Hsi Breakdown of academic impact, for papers by Brad S. Kahl Breakdown of academic impact, for papers by Kristie A. Blum Breakdown of academic impact, for papers by Luca Baldini Breakdown of academic impact, for papers by Armando López‐Guillermo Breakdown of academic impact, for papers by Luis Fayad Breakdown of academic impact, for papers by Iwona Włodarska Breakdown of academic impact, for papers by Vincent Ribrag Breakdown of academic impact, for papers by Sonali M. Smith
Rankless by CCL
2026